{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:09:59Z","timestamp":1790762999277,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.jcmgh.2022.02.015","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T12:06:42Z","timestamp":1646050002000},"page":"1625-1647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis"],"prefix":"10.1016","volume":"13","author":[{"given":"Kahealani","family":"Uehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimarie","family":"Sostre-Col\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Santoleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly-Ann","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 L.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-5649","authenticated-orcid":false,"given":"Paul M.","family":"Titchenell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2022.02.015_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib3","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib6","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","article-title":"Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40608-017-0168-y","article-title":"Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery","volume":"4","author":"Parker","year":"2017","journal-title":"BMC Obes"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib10","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib12","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoporteins in patients with NAFLD","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tem.2017.03.003","article-title":"Unraveling the regulation of hepatic metabolism by insulin","volume":"28","author":"Titchenell","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbalip.2012.01.006","article-title":"Postprandial metabolism of meal triglyceride in humans","volume":"1821","author":"Lambert","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib19","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav9701","article-title":"Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis","volume":"11","author":"Amin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"Ben-Sahra","year":"2017","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/nature09584","article-title":"mTORC1 controls fasting-induced ketogenesis and its modulation by ageing","volume":"468","author":"Sengupta","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Garami","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib26","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","article-title":"Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways","volume":"14","author":"Yecies","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cmet.2011.09.001","article-title":"Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c","volume":"14","author":"Wan","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cmet.2016.04.022","article-title":"Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production","volume":"23","author":"Titchenell","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117000","article-title":"Livers with constitutive mTORC1 activity resist steatosis independent of feedback suppression of akt","volume":"10","author":"Kenerson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018075","article-title":"Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation","volume":"6","author":"Kenerson","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tem.2013.04.001","article-title":"The regulation of ApoB metabolism by insulin","volume":"24","author":"Haas","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib34","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1172\/JCI96036","article-title":"mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion","volume":"127","author":"Quinn","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib35","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1172\/JCI61248","article-title":"Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice","volume":"122","author":"Ai","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmet.2014.05.001","article-title":"Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition","volume":"20","author":"Umemura","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.23094","article-title":"Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis","volume":"50","author":"Fujita","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib39","doi-asserted-by":"crossref","first-page":"14056","DOI":"10.1073\/pnas.0706517104","article-title":"Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance","volume":"104","author":"Tremblay","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib40","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2004-0921","article-title":"Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance","volume":"146","author":"Khamzina","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin is essential for the hepatic fibrogenic response to chronic liver injury","volume":"37","author":"Leclercq","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164191","article-title":"Evaluation of methionine content in a high-fat and choline-deficient diet on body weight gain and the development of non-alcoholic steatohepatitis in mice","volume":"11","author":"Chiba","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib44","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1126\/science.aay0542","article-title":"An AMPK\u2013caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib45","doi-asserted-by":"crossref","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","article-title":"Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment","volume":"305","author":"Roth","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A\u00a0complex interplay between Akt, TSC2 and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochemi Soc Transact"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib47","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1194\/jlr.D500019-JLR200","article-title":"Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339","volume":"46","author":"Millar","year":"2005","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib48","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1074\/jbc.M706628200","article-title":"Hepatic CTP:phosphocholine cytidylyltransferase-\u03b1 is a critical predictor of plasma high density lipoprotein and very low density lipoprotein","volume":"283","author":"Jacobs","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cmet.2006.03.007","article-title":"The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis","volume":"3","author":"Li","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib50","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.bbalip.2011.06.021","article-title":"Phosphatidylcholine protects against steatosis in mice but not non-alcoholic steatohepatitis","volume":"1811","author":"Niebergall","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib51","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A\u00a0lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0021-9258(19)50785-2","article-title":"The function of cytidine coenzyme in the biosynthesis of phospholipides","volume":"222","author":"Kennedy","year":"1956","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib53","doi-asserted-by":"crossref","first-page":"47402","DOI":"10.1074\/jbc.M404027200","article-title":"Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase \u03b1 in mice decreases plasma high density and very low density lipoproteins","volume":"279","author":"Jacobs","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-\u03b2 dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1194\/jlr.P089953","article-title":"Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease","volume":"60","author":"Pirola","year":"2019","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib56","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.2337\/diabetes.52.12.2905","article-title":"Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement","volume":"52","author":"Ono","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib57","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1038\/ncomms6190","article-title":"Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors","volume":"5","author":"Haeusler","year":"2014","journal-title":"Nat Comm"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib58","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib59","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1128\/MCB.19.5.3760","article-title":"ADD1\/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose","volume":"19","author":"Foretz","year":"2015","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib60","doi-asserted-by":"crossref","first-page":"10105","DOI":"10.1074\/jbc.M600272200","article-title":"FoxO1 regulates multiple metabolic pathways in the liver effects on gluconeogenic, glycolytic, and lipogenic gene expression","volume":"281","author":"Zhang","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib61","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1074\/jbc.273.10.5785","article-title":"Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein","volume":"273","author":"Sakai","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0092-8674(00)81362-8","article-title":"Sterol resistance in CHO cells traced to point mutation in SREBP cleavage\u2013activating protein xianxin","volume":"87","author":"Hua","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib63","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cmet.2016.10.012","article-title":"Physiological suppression of lipotoxic liver damage by complementary actions of HDAC3 and SCAP\/SREBP","volume":"24","author":"Papazyan","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/cancers10120465","article-title":"mTOR activation in liver tumors is associated with metabolic syndrome and non-alcoholic steatohepatitis in both mouse models and humans","volume":"10","author":"Okuno","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"D\u00fcvel","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2011.07.038","article-title":"Role of S6K1 in regulation of SREBP1c expression in the liver","volume":"412","author":"Li","year":"2011","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib68","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","article-title":"Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies","volume":"14","author":"Shah","year":"2004","journal-title":"Curr Biol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib69","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","article-title":"Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC\u03b1, but Not S6K1","volume":"11","author":"Guertin","year":"2006","journal-title":"Dev Cell"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib70","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.2337\/diabetes.48.10.2022","article-title":"Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia","volume":"48","author":"O\u2019Doherty","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib71","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1016\/S0021-9258(18)69166-5","article-title":"The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes","volume":"263","author":"Yao","year":"1988","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib72","first-page":"1399","article-title":"Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation","volume":"22","author":"Buchman","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib73","first-page":"851","article-title":"A\u00a0genome-first approach to mortality and metabolic phenotypes in MTARC1 homozygotes","volume":"2","author":"Schneider","year":"2021","journal-title":"Med (NY)"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib74","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2020.04.021","article-title":"MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans","volume":"73","author":"Luukkonen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib75","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib76","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/hmg\/ddx159","article-title":"Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis","volume":"26","author":"Ehrhardt","year":"2017","journal-title":"Hum Mol Gen"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib77","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","article-title":"PNPLA3 gene in liver diseases","volume":"65","author":"Tr\u00e9po","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib78","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2017.02.014","article-title":"Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD","volume":"67","author":"Luukkonen","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib79","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185396","article-title":"Association of MTTP gene variants with pediatric NAFLD: a candidate-gene-based analysis of single nucleotide variations in obese children","volume":"12","author":"Dai","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12881-015-0242-6","article-title":"MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study","volume":"16","author":"Hsiao","year":"2015","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib82","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib83","first-page":"ra24","article-title":"Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice","volume":"5","author":"Bronson","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib84","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cmet.2007.08.006","article-title":"Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver","volume":"6","author":"Matsumoto","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib85","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A\u00a0simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.chroma.2017.07.063","article-title":"Optimization of normal phase chromatographic conditions for lipid analysis and comparison of associated detection techniques","volume":"1514","author":"Abreu","year":"2017","journal-title":"J\u00a0Chromatogr A"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100093","article-title":"Carboxylesterase 1d (Ces1d) does not contribute to cholesteryl ester hydrolysis in the liver","volume":"62","author":"Lian","year":"2021","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib88","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cmet.2009.10.004","article-title":"Akt2 is required for hepatic lipid accumulation in models of insulin resistance","volume":"10","author":"Leavens","year":"2009","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2022.02.015_bib89","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X2200042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X2200042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:31:53Z","timestamp":1762453913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X2200042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2352345X2200042X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2022.02.015","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2022.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}